Quiver Bioscience

Executive Summary

Quiver Bioscience is a private, preclinical-stage biotechnology company based in Cambridge, MA, founded in 2020 with a mission to develop transformational medicines for brain disorders. The company leverages a proprietary platform integrating novel artificial intelligence with human disease models to accelerate target discovery and drug development. By combining in silico predictions with biologically relevant human systems, Quiver aims to address the high failure rates and long timelines typical of central nervous system (CNS) drug development. The platform is positioned as a best-in-class partner for transitioning from target identification to clinical candidates, with a focus on genetically validated and disease-relevant targets. Currently operating in a capital-efficient manner, Quiver Bioscience has not publicly disclosed specific pipeline programs, total funding, or valuation. The company is at a very early stage, with no disclosed preclinical or clinical data. Its success hinges on platform validation through internal programs or collaborations. Given the competitive landscape of AI-driven drug discovery for CNS disorders, Quiver's differentiation rests on the quality of its human disease models and AI algorithms. Near-term potential catalysts include securing a significant partnership or advancing a lead program into IND-enabling studies, though these events remain speculative without disclosed timelines.

Upcoming Catalysts (preview)

• Q4 2026Announcement of lead program target or preclinical validation data35% success
• H1 2027Strategic partnership with a large pharmaceutical company for platform access30% success